ESSA Pharma

Developing novel therapies for the treatment of prostate cancer

ESSA is focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. The company has developed a new class of drugs, the “anitens”. These drugs interrupt androgen-driven biology in a novel manner and are active even in the setting of resistance to current anti-androgen therapies.

Status
NASDAQ: EPIX
Year of Investment
2021
Strategy
Life Sciences
Location
Vancouver, British Columbia